We seek for new chemical compounds and deliver to the world.
Chemiteras is a fine chemical company contributing to the health and longevity.
                                        
                                        
                                        | Chemiteras,Inc. | |
|---|---|
| Company name | Chemiteras,Inc. | 
| Head Office | 3-chome-24-5 Shinnyokohama,Kohoku Ward, Yokohama, Kanagawa, 222-0033, Japan | 
| company representative | Tokinori Terada | 
Advisor  | 
                      Makio Koga | 
| foundation | 2017.9.13 | 
| Business | R&D of chemical compounds. Machinery development. Utilization of intellectual properties. Planning, manufacturing, sales of health food.  | 
                                    
| E-mail address | info@chemiteras.com | 
| 見出し | ここをクリックして表示したいテキストを入力してください。 | 
| Sep.2022 | Chemiteras has been appointed as a brand influencer for Karada Laboratory's BI-HARI, a wholly owned subsidiary of Cross Marketing Group, Inc.(listed on the TSE Prime Market). ■Chemiteras becomes a brand influencer for Karada Laboratory's BI-HARI  | 
                              
|---|---|
| Jun.2022 | Chemiteras has signed an agreement for exclusive sales right in Japan with Safely2Prosperity LLC (Headquarters: Massachusetts, USA, Representative Director: John Norris), a leading company that provides cloud-based software as a corporate and organizational management system for next-generation infectious diseases.  ■ Chemiteras Inc. and Safely2Prosperity LLC Signed an Agreement for Exclusive Sales Right in Japan(Japanese only) Additionally, John Norris, the founder&CEO of Safely2Prosperity, has been appointed as one of our advisors.  | 
                              
| Jan.2022 | 
                                    SIRTUP, a dietary supplement containing deazaflavine, a seed compound for drug discovery based on our patented technology, has been released by Life Science Lab Co. ■SIRTUP Product Overview(Japanese only)  | 
                              
| Oct.2021 | Release: News release published in multiple media including PRTIMES ■「Successful development and patent acquisition of a compound showing mitochondrial activity」(Japanese only)  | 
                              
| Sep.2021 | “UNIPLAT” was officially launched on September 28, 2021. ■UNIPLAT(https://www.uniplat.social)  | 
                              
| Nov.2020 | The online support platform for researchers "UNIPLAT", which we are entrusted with system development, has been published in the Group of Nations, a public relations magazine of the international summits. ■Group of Nations / G20 GLOBAL BRIEFING REPORT 2020 (UNIPLAT is on pages 156 and 157) This magazine is an official publication for international conferences such as G8, G20, APEC.  | 
                              
| Aug.2019 | Signed an advisory agreement with Dr. Torkel Falkenberg, deputy head for Karolinska Institutet Center for Social Sustainability in Sweden. | 
| Mar.2019 | Joint development:  Patent applications of a seed compound for the brain cancer drug  | 
                              
| Feb.2019 | In-house development: Patent application of a seed compound for the mitochondrial related drug  | 
                              
| Aug.2018 | In-house development: Patent applications of a seed compound for the Hyperuricemia treatment drug  | 
                              
| 見出し | ここをクリックして表示したいテキストを入力してください。テキストは「右寄せ」「中央寄せ」「左寄せ」といった整列方向、「太字」「斜体」「下線」「取り消し線」、「文字サイズ」「文字色」「文字の背景色」など細かく編集することができます。 |